Invesco Ltd. Raises Stock Position in ADMA Biologics Inc (NASDAQ:ADMA)

Key Points

• Invesco Ltd. increased its stake in ADMA Biologics by 13.9%, purchasing an additional 1,570,649 shares, bringing its total ownership to approximately 12.87 million shares, valued at around $255 million.
• ADMA Biologics reported $0.15 EPS for the last quarter, beating expectations of $0.14, alongside revenues of $121.98 million, a 13.8% year-over-year increase.
• Analyst ratings have varied, with Raymond James raising their target price from $25 to $32 while Wall Street Zen lowered their rating from "hold" to "sell".

Invesco Ltd. lifted its stake in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 13.9% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 12,866,904 shares of the biotechnology company's stock after acquiring an additional 1,570,649 shares during the quarter. Invesco Ltd. owned approximately 5.42% of ADMA Biologics worth $255,279,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the stock. Townsquare Capital LLC purchased a new position in shares of ADMA Biologics during the first quarter worth approximately $546,000. Citigroup Inc. boosted its stake in shares of ADMA Biologics by 6.3% during the first quarter. Citigroup Inc. now owns 1,001,852 shares of the biotechnology company's stock valued at $19,877,000 after purchasing an additional 59,669 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of ADMA Biologics by 0.9% during the first quarter. Charles Schwab Investment Management Inc. now owns 2,462,005 shares of the biotechnology company's stock valued at $48,846,000 after purchasing an additional 21,711 shares in the last quarter. PNC Financial Services Group Inc. boosted its stake in shares of ADMA Biologics by 24.3% during the first quarter. PNC Financial Services Group Inc. now owns 23,325 shares of the biotechnology company's stock valued at $463,000 after purchasing an additional 4,553 shares in the last quarter. Finally, Alberta Investment Management Corp boosted its stake in shares of ADMA Biologics by 17.8% during the first quarter. Alberta Investment Management Corp now owns 294,250 shares of the biotechnology company's stock valued at $5,838,000 after purchasing an additional 44,557 shares in the last quarter. 75.68% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on ADMA shares. Raymond James Financial increased their price objective on shares of ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research note on Thursday, May 8th. Wall Street Zen downgraded shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research note on Friday, May 9th.

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, Director Steve Elms sold 194,749 shares of the firm's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $20.24, for a total value of $3,941,719.76. Following the completion of the sale, the director directly owned 87,330 shares in the company, valued at $1,767,559.20. This trade represents a 69.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Lawrence P. Guiheen sold 20,000 shares of the firm's stock in a transaction on Monday, June 9th. The stock was sold at an average price of $20.96, for a total transaction of $419,200.00. Following the completion of the transaction, the director directly owned 94,830 shares of the company's stock, valued at approximately $1,987,636.80. This represents a 17.42% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 464,621 shares of company stock worth $9,644,269 over the last three months. Corporate insiders own 3.50% of the company's stock.

ADMA Biologics Stock Up 0.1%

ADMA traded up $0.02 during trading on Friday, hitting $16.99. The stock had a trading volume of 3,108,545 shares, compared to its average volume of 3,534,720. The company has a market capitalization of $4.05 billion, a PE ratio of 19.76 and a beta of 0.38. ADMA Biologics Inc has a twelve month low of $13.50 and a twelve month high of $25.67. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.78 and a current ratio of 5.33. The stock has a 50 day simple moving average of $18.29 and a two-hundred day simple moving average of $18.85.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.01. The company had revenue of $121.98 million during the quarter, compared to the consensus estimate of $121.77 million. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. ADMA Biologics's revenue was up 13.8% compared to the same quarter last year. During the same period last year, the firm earned $0.13 earnings per share. On average, research analysts predict that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.